Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial-Reference-Cited by-同舟云学术

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

Published:2007-12 Issue:9605 Volume:370 Page:2103-2111
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Escudier Bernard,Pluzanska Anna,Koralewski Piotr,Ravaud Alain,Bracarda Sergio,Szczylik Cezary,Chevreau Christine,Filipek Marek,Melichar Bohuslav,Bajetta Emilio,Gorbunova Vera,Bay Jacques-Olivier,Bodrogi Istvan,Jagiello-Gruszfeld Agnieszka,Moore Nicola

Publisher

Elsevier BV

Subject

General Medicine

Reference43 articles.

1. Estimates of the cancer incidence and mortality in Europe in 2006;Ferlay;Ann Oncol,2007

2. Renal cancer: molecular mechanisms and newer therapeutic options;Karumanchi;Curr Opin Nephrol Hypertens,2002

3. Cancer: principles and practice of oncology;DeVita,2001

4. Renal-cell carcinoma;Motzer;N Engl J Med,1996

5. Nonmetastatic renal cell carcinoma: is it really possible to define rational guidelines for post treatment follow up;Rouviere;Nat Clin Pract Oncol,2006

Cited by 2026 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Temporary treatment cessation compared with continuation of tyrosine kinase inhibitors for adults with renal cancer: the STAR non-inferiority RCT;Health Technology Assessment;2024-08

2. TGFBI promotes proliferation and epithelial–mesenchymal transition in renal cell carcinoma through PI3K/AKT/mTOR/HIF-1α pathway;Cancer Cell International;2024-07-27

3. Milestones in tumor vascularization and its therapeutic targeting;Nature Cancer;2024-06-25

4. Multidisciplinary systemic and local therapies for metastatic renal cell carcinoma: a narrative review;Expert Review of Anticancer Therapy;2024-06-03

5. Von Hippel–Lindau protein signalling in clear cell renal cell carcinoma;Nature Reviews Urology;2024-05-02